Benefits and risks of investing in GLP-1 stocks
Here are some factors to consider before you put money to work in GLP-1 stocks.
- The surge in revenue and profits that key players have experienced from their GLP-1 franchises can also create attractive investment opportunities for long-term shareholders.
- The GLP-1 market is attracting numerous companies, including both established pharmaceutical giants and smaller biotech firms.
- Growing competition could create opportunities for numerous winners to control profitable slices of the market.
- The high demand for GLP-1 drugs has driven up some manufacturers' stock prices, so there are justifiable concerns in certain market periods about whether these stocks are overvalued.
- Investing in clinical-stage companies working on GLP-1 drugs is a far higher-risk, higher-reward venture than putting cash into an established pharmaceutical company with a broad product portfolio.
If you prefer a more diversified approach, consider investing in ETFs that hold shares of leaders in the GLP-1 industry. Some ETFs that provide exposure to the GLP-1 market include:
- Roundhill GLP-1 & Weight Loss ETF (OZEM -0.44%)
- Amplify Weight Loss Drug & Treatment ETF (THNR +0.35%)
- Tema Obesity & Cardiometabolic ETF (HRTS -0.92%)
However, if you're confident in your ability to select promising GLP-1 companies and understand the risks involved, picking individual stocks might be a more attractive option.
The bottom line
The GLP-1 market presents a significant investment opportunity. However, choosing individual stocks and funds in this space requires careful consideration of your risk tolerance and investment objectives.
Before you put cash to work in GLP-1 companies, focus on businesses with differentiated drug candidates, a robust financial foundation, and the manufacturing capabilities to meet high demand in the future from healthcare consumers. Be aware that news related to clinical trial results, approvals, or safety concerns can cause significant fluctuations in individual stock prices.
The global GLP-1 market is entering an acceleration phase, with some analysts forecasting that it could reach $268 billion by the early 2030s. Long-term investors might want to capitalize on this reality by scooping up shares of one or more GLP-1 stocks.
